BEAMSTART Logo

Conavi Medical Shareholders Approve the Proposed Amalgamation Between Titan and Conavi 

GlobeNewswire LogoGlobeNewswire2d ago

Conavi Medical Shareholders Approve the Proposed Amalgamation Between Titan and Conavi  - GlobeNewswire

Quick Summary:

Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions and Titan has attempted to identify important factors that could cause actual actions, events, conditions, results, performance or achievements to differ materially from those described in forward-looking statements, Titan cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements.

"This vote underscores their confidence in the Amalgamation with Titan and the exciting commercial path we have set for the future of our proprietary Novasight Hybrid™ System, the first technology platform to combine both IVUS and OCT to enable simultaneous and co-registered imaging of coronary arteries.” "The completion of the Conavi shareholder approval is another important step in the process to close the Transaction” said Paul Cataford, Titan’s Interim CEO and Board Chairman.

These forward-looking statements reflect management’s current beliefs with respect to future events, and are based on information currently available to management that, while considered reasonable by management as of the date on which the statements are made, are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in actions, events, conditions, results, performance or achievements to be materially different from those projected in the forward-looking statements.

or

Article Details

Author / Journalist: Titan Medical Inc.

Category: Technology

Markets:

Topics:

Source Website Secure: Yes (HTTPS)

News Sentiment: Negative

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-09-26 @ 15:53:00 (2 days ago)

News Timezone: GMT +8:00

News Source URL: globenewswire.com

Language: English

Article Length: 1245 words

Reading Time: 7 minutes read

Sentences: 34 lines

Sentence Length: 37 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © GlobeNewswire

News ID: 22728892

View Article Analysis

About GlobeNewswire

Main Topics: Technology

Official Website: globenewswire.com

Year Established: 1998

Headquarters: China

News Last Updated: 1 days ago

Coverage Areas: China

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #116

Publisher Details

Frequently Asked Questions

How long will it take to read this news story?

The story "Conavi Medical Shareholders Approve the Proposed Amalgamation Between Titan and Conavi " has 1245 words across 34 sentences, which will take approximately 6 - 11 minutes for the average person to read.

Which news outlet covered this story?

The story "Conavi Medical Shareholders Approve the Proposed Amalgamation Between Titan and Conavi " was covered 2 days ago by GlobeNewswire, a news publisher based in China.

How trustworthy is 'GlobeNewswire' news outlet?

GlobeNewswire is a fully independent (privately-owned) news outlet established in 1998 that covers mostly technology news.

The outlet is headquartered in China and publishes an average of 0 news stories per day.

It's most recent story was published 1 days ago.

What do people currently think of this news story?

The sentiment for this story is currently Negative, indicating that people regard this as "bad news".

How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.
  • News ID: #22728892
  • URL: https://beamstart.com/news/conavi-medical-shareholders-approve-the-1727366075

BEAMSTART

BEAMSTART is a global entrepreneurship community, serving as a catalyst for innovation and collaboration. With a mission to empower entrepreneurs, we offer exclusive deals with savings totaling over $1,000,000, curated news, events, and a vast investor database. Through our portal, we aim to foster a supportive ecosystem where like-minded individuals can connect and create opportunities for growth and success.

© Copyright 2024 BEAMSTART. All Rights Reserved.